The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer

John Kaczmar, Ranee Mehra

Research output: Contribution to journalReview article

Abstract

Research over the last decade has determined that the gene rearrangement involving the anaplastic lymphoma kinase (ALK) gene is an oncogenic driver in approximately 5% of patients with non-small cell lung carcinoma (NSCLC). This review describes the discovery of the ALK translocation, development of ALK directed therapy, and acquired resistance to ALK directed therapy with a focus on the clinical data and efficacy of the most recently approved ALK inhibitor, ceritinib.

Original languageEnglish (US)
Pages (from-to)236-241
Number of pages6
JournalTherapeutic Advances in Respiratory Disease
Volume9
Issue number5
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Gene Rearrangement
ceritinib
anaplastic lymphoma kinase
Therapeutics
Research
Genes

Keywords

  • ALK translocation
  • ceritinib
  • NSCLC

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Pharmacology (medical)

Cite this

The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer. / Kaczmar, John; Mehra, Ranee.

In: Therapeutic Advances in Respiratory Disease, Vol. 9, No. 5, 2015, p. 236-241.

Research output: Contribution to journalReview article

@article{baa35e38948f47fc9d4b51923acac328,
title = "The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer",
abstract = "Research over the last decade has determined that the gene rearrangement involving the anaplastic lymphoma kinase (ALK) gene is an oncogenic driver in approximately 5{\%} of patients with non-small cell lung carcinoma (NSCLC). This review describes the discovery of the ALK translocation, development of ALK directed therapy, and acquired resistance to ALK directed therapy with a focus on the clinical data and efficacy of the most recently approved ALK inhibitor, ceritinib.",
keywords = "ALK translocation, ceritinib, NSCLC",
author = "John Kaczmar and Ranee Mehra",
year = "2015",
doi = "10.1177/1753465815597834",
language = "English (US)",
volume = "9",
pages = "236--241",
journal = "Therapeutic Advances in Respiratory Disease",
issn = "1753-4658",
publisher = "SAGE Publications Ltd",
number = "5",

}

TY - JOUR

T1 - The efficacy of ceritinib in patients with ALK-positive non-small cell lung cancer

AU - Kaczmar, John

AU - Mehra, Ranee

PY - 2015

Y1 - 2015

N2 - Research over the last decade has determined that the gene rearrangement involving the anaplastic lymphoma kinase (ALK) gene is an oncogenic driver in approximately 5% of patients with non-small cell lung carcinoma (NSCLC). This review describes the discovery of the ALK translocation, development of ALK directed therapy, and acquired resistance to ALK directed therapy with a focus on the clinical data and efficacy of the most recently approved ALK inhibitor, ceritinib.

AB - Research over the last decade has determined that the gene rearrangement involving the anaplastic lymphoma kinase (ALK) gene is an oncogenic driver in approximately 5% of patients with non-small cell lung carcinoma (NSCLC). This review describes the discovery of the ALK translocation, development of ALK directed therapy, and acquired resistance to ALK directed therapy with a focus on the clinical data and efficacy of the most recently approved ALK inhibitor, ceritinib.

KW - ALK translocation

KW - ceritinib

KW - NSCLC

UR - http://www.scopus.com/inward/record.url?scp=84942584242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942584242&partnerID=8YFLogxK

U2 - 10.1177/1753465815597834

DO - 10.1177/1753465815597834

M3 - Review article

C2 - 26229087

AN - SCOPUS:84942584242

VL - 9

SP - 236

EP - 241

JO - Therapeutic Advances in Respiratory Disease

JF - Therapeutic Advances in Respiratory Disease

SN - 1753-4658

IS - 5

ER -